Media
Press Releases
January 9, 2025
Lupin Receives Tentative Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel
January 9, 2025
Lupin Receives Tentative Approval from U.S. FDA for Ivacaftor Oral Granules
January 8, 2025
Lupin Receives EIR from U.S. FDA for its Pithampur Unit-1 Facility with VAI Classification
December 18, 2024
Lupin Receives Approval from U.S. FDA for Emtricitabine and Tenofovir Alafenamide Tablets
December 6, 2024
Lupin Receives Tentative Approval from U.S. FDA for Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension
November 28, 2024
Lupin Receives Tentative Approval from U.S. FDA for Sitagliptin and Metformin Hydrochloride Tablets
November 19, 2024
Lupin Receives Approval from U.S. FDA for Mixed Salts of a Single-Entity Amphetamine Extended-Release Capsules
November 19, 2024
Lupin Launches Bumetanide Injection, USP in the United States
November 8, 2024
Lupin Receives Tentative Approval from U.S. FDA for Raltegravir Tablets, USP
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product